Meeting
2024 ASCO Genitourinary Cancers Symposium
A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
Authors
Shun Zhang
Nanjing Drum Tower Hospital, Nanjing, China
Shun Zhang , Changwei JI , Guangxiang Liu , Hongqian Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05172440
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 420)
DOI
10.1200/JCO.2024.42.4_suppl.420
Abstract #
420
Poster Bd #
H2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.
First Author: Jing Chen
Poster
2013 ASCO Annual Meeting
A phase II clinical trial examining the impact of neoadjuvant axitinib on primary tumor response in patients with locally advanced clear cell renal cell carcinoma.
First Author: Jose A. Karam
Poster
2024 ASCO Annual Meeting
Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial.
First Author: Wei Guo
Poster
2024 ASCO Genitourinary Cancers Symposium
WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.
First Author: Yige Bao